Sustained Epstein-Barr virus detection in paediatric liver transplantation. Insights into the occurrence of late PTLD

被引:29
作者
D'Antiga, Lorenzo
Del Rizzo, Monica
Mengoli, Carlo
Cillo, Umberto
Guariso, Graziella
Zancan, Lucia
机构
[1] Univ Padua, Dept Paediat, I-35128 Padua, Italy
[2] Univ Padua, Dept Virol Microbiol & Med Biotechnol, I-35128 Padua, Italy
[3] Univ Padua, Dept Surg & Gastroenterol Sci, I-35128 Padua, Italy
关键词
D O I
10.1002/lt.20958
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Epstein-Barr virus (EBV) infection is the main cause of post-transplant lymphoproliferative disease (PTLD). Little is known on chronic carrier state and its relation with late PTLD. We aimed to study EBV infection in the long-term after paediatric liver transplantation (OLT). We conducted a retrospective review of 34 children monitored for a median of 5.8 years (range 1.5-17.7). 21 were IgG seronegative (group A) and 13 seropositive (group B) before OLT. Primary infection was the appearance of VCA-IgM or VCA-IgG or Real-Time Polymerase Chain Reaction (RT-PCR) in patients previously IgG seronegative; positive VCA-IgM or EA-IgG or RT-PCR lasting longer than 6 months was defined sustained viral detection (SVD). 18/21 patients of group A had a primary infection at a median time of 3 months after transplant (0.5-60). 14/18 of group A and 0/13 of group B had a SVD (P < 0.0001). Viral loads greater than 500 copies/10(5) mononuclear cells occur-red in 12/18 patients in group A and 0/13 patients in group B (P < 0.0001). The 3 patients who developed late PTLD (median time after OLT 47 months, range 15-121) were from group A, and presented with SVD before developing PTLD. In conclusion, EBV infection in seronegative patients at OLT is associated with greater viral loads and sustained viral detection. Late PTLD occurred only in naive patients with markers of SVD. Three to 4 monthly long-term monitoring of EBV in pre-OLT naive patients might help preventing the occurrence of late PTLD.
引用
收藏
页码:343 / 348
页数:6
相关论文
共 28 条
[21]   Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients [J].
Rooney, CM ;
Smith, CA ;
Ng, CYC ;
Loftin, SK ;
Sixbey, JW ;
Gan, YJ ;
Srivastava, DK ;
Bowman, LC ;
Krance, RA ;
Brenner, MK ;
Heslop, HE .
BLOOD, 1998, 92 (05) :1549-1555
[22]   Use of quantitative competitive PCR to measure Epstein-Barr virus genome load in the peripheral blood of pediatric transplant patients with lymphoproliferative disorders [J].
Rowe, DT ;
Qu, L ;
Reyes, J ;
Jabbour, N ;
Yunis, E ;
Putnam, P ;
Todo, S ;
Green, M .
JOURNAL OF CLINICAL MICROBIOLOGY, 1997, 35 (06) :1612-1615
[23]   Cellular immunity to Epstein-Barr virus in liver transplant recipients treated with rituximab for post-transplant lymphoproliferative disease [J].
Savoldo, B ;
Rooney, CM ;
Quiros- Tejeira, RE ;
Caldwell, Y ;
Wagner, HJ ;
Lee, T ;
Finegold, MJ ;
Dotti, G ;
Heslop, HE ;
Goss, JA .
AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 (03) :566-572
[24]   Anti-CD20 monoclonal antibody (rituximab) treatment for Epstein-Barr virus-associated, B-cell Lymphoproliferative disease in pediatric liver transplant recipients [J].
Serinet, MO ;
Jacquemin, E ;
Habes, D ;
Debray, D ;
Fabre, M ;
Bernard, O .
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2002, 34 (04) :389-393
[25]   Characteristics of Epstein-Barr virus primary infection in pediatric liver transplant recipients [J].
Smets, F ;
Bodeus, M ;
Goubau, P ;
Reding, R ;
Otte, JB ;
Buts, JP ;
Sokal, EM .
JOURNAL OF HEPATOLOGY, 2000, 32 (01) :100-104
[26]   Epstein-Barr virus-related lymphoproliferation in children after liver transplant: Role of immunity, diagnosis, and management [J].
Smets, F ;
Sokal, EM .
PEDIATRIC TRANSPLANTATION, 2002, 6 (04) :280-287
[27]  
STARZL TE, 1984, LANCET, V1, P583
[28]   Mechanisms of disease - Persistence of the Epstein-Barr virus and the origins of associated lymphomas [J].
Thorley-Lawson, DA ;
Gross, A .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (13) :1328-1337